Medications for Obesity

医学 利拉鲁肽 减肥 奥利斯特 不利影响 肥胖 芬特明 安非他酮 恶心 食欲 2型糖尿病 内科学 内分泌学 糖尿病 戒烟 病理
作者
Kimberly A. Gudzune,Robert F. Kushner
出处
期刊:JAMA [American Medical Association]
卷期号:332 (7): 571-571 被引量:141
标识
DOI:10.1001/jama.2024.10816
摘要

Importance Obesity affects approximately 19% of women and 14% of men worldwide and is associated with increased morbidity. Antiobesity medications (AOMs) modify biological processes that affect appetite and significantly improve outcomes, such as type 2 diabetes, hypertension, and dyslipidemia. Observations AOMs should be administered in combination with lifestyle interventions and can be classified according to their mechanisms of action. Orlistat modifies digestive tract absorption and causes gastrointestinal adverse effects, such as oily fecal spotting and urgency, in more than 25% of patients. Centrally acting drugs, such as phentermine-topiramate and naltrexone-bupropion, regulate appetite in the brain and are associated with constipation in approximately 20% of patients, although the incidence of other adverse effects (eg, paresthesia, nausea) varies by medication. Nutrient-stimulated hormone-based medications, such as liraglutide, semaglutide, and tirzepatide, mimic the actions of enteropancreatic hormones that modify central appetite regulation and provide multiple cardiometabolic weight-loss benefits. Adverse effects of these drugs include nausea (28%-44%), diarrhea (21%-30%), and constipation (11%-24%). The relative potency of adult obesity medications has been studied in meta-analyses. Compared with placebo, orlistat was associated with 3.1% greater weight loss (52 randomized clinical trials [RCTs]; 16 964 participants), phentermine-topiramate was associated with 8.0% greater weight loss (5 RCTs; 3407 participants), naltrexone-bupropion was associated with 4.1% greater weight loss (6 RCTs; 9949 participants), liraglutide was associated with 4.7% greater weight loss (18 RCTs; 6321 participants), semaglutide was associated with 11.4% greater weight loss (5 RCTs; 4421 participants), and tirzepatide 15 mg was associated with 12.4% greater weight loss (6 RCTs; 1972 participants). Conclusion and Relevance Obesity is associated with increased morbidity. Antiobesity medications are effective adjunctive therapy to lifestyle changes for improved weight loss and health outcomes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
周南发布了新的文献求助10
刚刚
Lucas应助MY采纳,获得10
刚刚
糖小白完成签到,获得积分10
刚刚
1秒前
yulu发布了新的文献求助10
1秒前
huhuiya完成签到 ,获得积分10
2秒前
2秒前
延误发布了新的文献求助10
2秒前
减肥为窈窕完成签到,获得积分10
2秒前
勤恳依琴发布了新的文献求助10
4秒前
hoangphong完成签到,获得积分10
4秒前
量子星尘发布了新的文献求助10
6秒前
7秒前
酷酷世德完成签到,获得积分10
7秒前
7秒前
科研通AI2S应助周南采纳,获得10
7秒前
西溪完成签到,获得积分10
9秒前
LLR发布了新的文献求助10
11秒前
Jiaowen发布了新的文献求助10
11秒前
11秒前
ini发布了新的文献求助10
14秒前
董董完成签到,获得积分10
14秒前
小透明应助温柔柜子采纳,获得30
14秒前
14秒前
16秒前
可靠的薯片完成签到,获得积分10
16秒前
不可思宇完成签到,获得积分10
16秒前
yhengdyheng发布了新的文献求助10
18秒前
18秒前
18秒前
18秒前
田様应助董董采纳,获得10
19秒前
猪突猛进发布了新的文献求助20
19秒前
cccr发布了新的文献求助10
19秒前
20秒前
包容耳机完成签到,获得积分20
21秒前
Z6745发布了新的文献求助10
21秒前
21秒前
21秒前
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Clinical Microbiology Procedures Handbook, Multi-Volume, 5th Edition 临床微生物学程序手册,多卷,第5版 2000
List of 1,091 Public Pension Profiles by Region 1621
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] | NHBS Field Guides & Natural History 1500
The Victim–Offender Overlap During the Global Pandemic: A Comparative Study Across Western and Non-Western Countries 1000
King Tyrant 720
Sport, Social Media, and Digital Technology: Sociological Approaches 650
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5594094
求助须知:如何正确求助?哪些是违规求助? 4679802
关于积分的说明 14811596
捐赠科研通 4645803
什么是DOI,文献DOI怎么找? 2534749
邀请新用户注册赠送积分活动 1502769
关于科研通互助平台的介绍 1469452